Aignostics

Congrats again to the Aignostics team and collaborators on this publication in NEJM AI! In particular, congratulations to co-first authors Jonas Dippel and Dr. med. Niklas Prenißl as well as Aignostics team members and supervisors Tobias Winterhoff, Lukas Ruff, Klauschen Frederick, Klaus-Robert Müller, and Maximilian Alber. Paper: https://lnkd.in/evySat8e

Congrats to Aignostics on their successful round of Series B financing. Collaboration between Mayo Clinic and Aignostics seeks to develop foundation models for pathology, leveraging AI to enhance navigation amid the nuanced and complex field of precision medicine. #collaboration #innovation #ai

👏 Congratulations to our portfolio company Aignostics on raising $34 million in Series B financing. The global artificial intelligence company turns complex multi-modal pathology data into transformative insights. With this additional funding Aignostics will build new product offerings for biopharmaceutical clients, fuel growth within the US, and develop a leading foundation model for pathology in collaboration with Mayo Clinic.    💰This round was led by ATHOS, with investments from Mayo Clinic and growth financing from HTGF | High-Tech Gründerfonds, alongside support from existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA FUND Management GmbH, and VC Fonds Technologie managed by IBB Ventures. In total, Aignostics has now raised over $55 million, reflecting investors’ confidence in its differentiated AI models and clear commercial strategy. 🗯️ Viktor Matyas, CEO and Co-Founder of Aignostics, says: “2024 has been a pivotal year for us that has included a major strategic collaboration with Bayer and the launch of our first foundation model, RudolfV. With RudolfV, we’ve gained the ability to quickly develop cost-efficient algorithms that generalize to the real-world. Now with this new round of funding, we’re turning our most popular algorithms into products that will help usher in an era of truly generalizable AI for computational pathology.” 🗨️ Niels Sharman, Senior Investment Manager at HTGF, adds: “We have been thoroughly impressed by Aignostics' progress and their cutting-edge AI platform, which we believe will have a transformative impact on Pharma R&D. It is a pleasure working with such a talented team, and we are excited to significantly increase our investment to support their continued growth. We look forward to being part of their ongoing journey toward success.” Learn more by following the link in the comments ⬇️

🙌 We are proud to announce that our portfolio company Aignostics has successfully closed their $34M Series B! The round was led by ATHOS (Julian Zachmann), with investments from Mayo Clinic and HTGF | High-Tech Gründerfonds, alongside support from existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA FUND Management GmbH, and IBB Ventures. In total, Aignostics has now raised over $55 million, reflecting investors' confidence in its differentiated AI models and clear commercial strategy. Kudos to the incredible team around the founders Viktor Matyas and Maximilian Alber! 🚀 (Link to press release in comments)

Thrilled to welcome our new investors ATHOS, Mayo Clinic, and HTGF | High-Tech Gründerfonds! We will use this new funding to grow our product offering, expand our US presence, and develop new foundation models in collaboration with Mayo Clinic. Full PR below!

🚀 Exciting News! 🚀 We are thrilled to announce our oversubscribed $34M Series B funding round, led by ATHOS, with investments from Mayo Clinic and HTGF | High-Tech Gründerfonds Opportunity Fund, as well as existing investors. The new funding will support several strategic initiatives, including: • Collaborative development of foundation models and biopharma product offerings with Mayo Clinic. • Launch of scaled “plug-and-play” products for a range of indications and tasks, including tumor micro-environment and biomarker profiling. • Continued expansion into the US with additional headcount and support for US partners. Read our full announcement here: https://lnkd.in/eQ9uY9QT

Aignostics will have a poster at #SITC2024 next week! Our Head of Data Science Biopharma, Cornelius Böhm, will be presenting a poster (Abstract 1200) titled "Artificial intelligence image models optimizing tumor vs immune cell profiling for accurate biomarker analysis in NSCLC precision drug development" on Saturday, November 9th. Thank you to our collaborators at Bayer including Vasiliki Pelekanou MD PhD and team. Want to learn more about the work we are doing? Reach out: https://lnkd.in/eM5b929E Society for Immunotherapy of Cancer (SITC) #SITC #conference #houston #aignostics #AI #artificialintelligence #precisionmedicine #healthcare #innovation #machinelearning

📣 I am excited to share that our paper: AI-Based Anomaly Detection for Clinical-Grade Histopathological Diagnostics has now been published in NEJM AI. 💡 Detecting rare diseases is challenging as often not enough training data is available to reliably train a deep learning classifier. We circumvent this by proposing an anomaly detection approach which learns the characteristics of healthy tissue and common findings and then detects any deviation. 🛠️ We compare two promising approaches. (1) using representation distances from SSL/foundation models and (2) contrasting normal examples with images from other tissue types which helps to learn a tight decision boundary around the normal data (outlier exposure). 🚀 On two large clinical cohorts of gastrointestinal biopsies, we demonstrate that our anomaly detection approach can reliably detect a broad spectrum of anomalous pathologies, including rare cancer types. 🙏 Special thanks to Dr. med. Niklas Prenißl who co-first authored this work and taught me a lot about pathology! Further, we had stellar supervision by Lukas Ruff, Klaus-Robert Müller, Klauschen Frederick and amazing contributions by all other co-authors: Julius Hense, Philipp L., Tobias Winterhoff, Simon Schallenberg, Marius Kloft, Oliver Buchstab, David Horst, and Maximilian Alber. Read the paper: https://lnkd.in/e8eBiYUx Technische Universität Berlin Charité - Universitätsmedizin Berlin Ludwig-Maximilians-Universität München University of Kaiserslautern (TU-KL) BIFOLD - Berlin Institute for the Foundations of Learning and Data Aignostics

https://lnkd.in/d_83q4yx Check out our latest paper on AI based anomaly detection in histopathology published today in NEJM AI in a collaboration between Ludwig-Maximilians-Universität München, Technische Universit��t Berlin, Charité - Universitätsmedizin Berlin, University of Kaiserslautern (TU-KL) and Aignostics.

Check out our recent publication in NEJM AI, “AI-Based Anomaly Detection for Clinical-Grade Histopathological Diagnostics” in which we establish the first effective clinical application of AI-based anomaly detection in histopathology and demonstrate high performance on a unique real-world collection of GI biopsies. Read the full paper here: https://lnkd.in/evySat8e Special congratulations to Aignostics team members Jonas Dippel, Tobias Winterhoff, and Lukas Ruff. Thank you to our collaborators: Technische Universität Berlin Charité - Universitätsmedizin Berlin Ludwig-Maximilians-Universität München University of Kaiserslautern (TU-KL) BIFOLD - Berlin Institute for the Foundations of Learning and Data #aignostics #publication #artificialintelligence #ai #digitalpathology #machinelearning #deeplearning #anomalydetection